(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.81%) $83.17
(1.04%) $1.943
(-0.35%) $2 339.10
(-0.05%) $27.52
(0.62%) $927.80
(-0.23%) $0.933
(-0.22%) $11.00
(-0.30%) $0.798
(0.25%) $92.11
Quarter results tomorrow
(bmo 2024-04-30)
Expected move: +/- 4.51%
Live Chart Being Loaded With Signals
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe...
Stats | |
---|---|
今日成交量 | 5.64M |
平均成交量 | 3.20M |
市值 | 159.86M |
EPS | £0 ( 2024-04-22 ) |
下一个收益日期 | ( £0 ) 2024-04-30 |
Last Dividend | £0 ( N/A ) |
Next Dividend | £0 ( N/A ) |
P/E | -3.05 |
ATR14 | £0.191 (0.39%) |
音量 相关性
Avacta Group PLC 相关性 - 货币/商品
Avacta Group PLC 财务报表
Annual | 2022 |
营收: | £9.65M |
毛利润: | £4.23M (43.83 %) |
EPS: | £-0.150 |
FY | 2022 |
营收: | £9.65M |
毛利润: | £4.23M (43.83 %) |
EPS: | £-0.150 |
FY | 2021 |
营收: | £2.94M |
毛利润: | £2.02M (68.58 %) |
EPS: | £-0.106 |
FY | 2020 |
营收: | £3.64M |
毛利润: | £2.18M (59.98 %) |
EPS: | £-0.0837 |
Financial Reports:
No articles found.
Avacta Group PLC
Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。